Tülin Tuğlular

1.4k total citations
25 papers, 174 citations indexed

About

Tülin Tuğlular is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Tülin Tuğlular has authored 25 papers receiving a total of 174 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 14 papers in Genetics and 4 papers in Oncology. Recurrent topics in Tülin Tuğlular's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (8 papers), Multiple Myeloma Research and Treatments (7 papers) and Chronic Myeloid Leukemia Treatments (7 papers). Tülin Tuğlular is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (8 papers), Multiple Myeloma Research and Treatments (7 papers) and Chronic Myeloid Leukemia Treatments (7 papers). Tülin Tuğlular collaborates with scholars based in Türkiye, Hong Kong and Lebanon. Tülin Tuğlular's co-authors include Tayfur Toptaş, Işık Atagündüz, Mahmut Bayık, Gerd Rippin, Zhijian Xiao, Işık Kaygusuz, Raymond Wong, Volkan Korten, Elif Tükenmez Tigen and Mohamed A. Yassin and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and European Journal of Gastroenterology & Hepatology.

In The Last Decade

Tülin Tuğlular

23 papers receiving 174 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tülin Tuğlular Türkiye 7 93 87 45 37 34 25 174
Alexander Coltoff United States 8 84 0.9× 66 0.8× 44 1.0× 27 0.7× 20 0.6× 25 167
Mathijs Willemsen Belgium 9 23 0.2× 62 0.7× 47 1.0× 78 2.1× 95 2.8× 15 254
Uroš Markovic Italy 8 95 1.0× 33 0.4× 60 1.3× 7 0.2× 32 0.9× 36 188
Hiraku Mori Japan 9 144 1.5× 91 1.0× 59 1.3× 19 0.5× 11 0.3× 23 219
Caroline Mayeur‐Rousse France 6 25 0.3× 50 0.6× 33 0.7× 14 0.4× 63 1.9× 16 131
Ana Kerguelen Spain 9 177 1.9× 224 2.6× 126 2.8× 104 2.8× 11 0.3× 11 275
Federica Portale Italy 6 23 0.2× 34 0.4× 50 1.1× 10 0.3× 71 2.1× 7 180
Norihiro Murakami Japan 6 43 0.5× 15 0.2× 27 0.6× 12 0.3× 19 0.6× 12 100
Zefarina Zulkafli Malaysia 10 108 1.2× 82 0.9× 39 0.9× 9 0.2× 25 0.7× 50 208
E. Küenzlen Germany 5 180 1.9× 27 0.3× 25 0.6× 13 0.4× 27 0.8× 7 270

Countries citing papers authored by Tülin Tuğlular

Since Specialization
Citations

This map shows the geographic impact of Tülin Tuğlular's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tülin Tuğlular with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tülin Tuğlular more than expected).

Fields of papers citing papers by Tülin Tuğlular

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tülin Tuğlular. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tülin Tuğlular. The network helps show where Tülin Tuğlular may publish in the future.

Co-authorship network of co-authors of Tülin Tuğlular

This figure shows the co-authorship network connecting the top 25 collaborators of Tülin Tuğlular. A scholar is included among the top collaborators of Tülin Tuğlular based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tülin Tuğlular. Tülin Tuğlular is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Toptaş, Tayfur, Ahmet Yanık, Fatma Arıkan, et al.. (2025). Second-line use of dasatinib and nilotinib in a real-world patient population with chronic phase chronic myeloid leukemia. Hematology. 30(1). 2478344–2478344. 1 indexed citations
3.
4.
Atagündüz, Işık, et al.. (2021). Splenectomy in İmmune Thrombocytopenia: A Retrospective Analysis of 25-Year Follow-up Data from a Tertiary Health Clinic. Indian Journal of Hematology and Blood Transfusion. 38(3). 516–521. 1 indexed citations
5.
Arıkan, Fatma, et al.. (2021). Real-life ruxolitinib experience in intermediate-risk myelofibrosis. Blood Research. 56(4). 322–331. 4 indexed citations
6.
Tigen, Elif Tükenmez, et al.. (2020). Rectal colonization with multidrug-resistant gram-negative bacteria in patients with hematological malignancies: a prospective study. Expert Review of Hematology. 13(8). 923–927. 13 indexed citations
7.
Yassin, Mohamed A., Alì Taher, Vikram Mathews, et al.. (2020). MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria. Cancer Medicine. 9(13). 4512–4526. 37 indexed citations
8.
9.
Taher, Alì, Mohamed A. Yassin, Zhijian Xiao, et al.. (2018). Impact of Myeloproliferative Neoplasms (MPNs) on Health-Related Quality of Life (HRQOL) and Medical Resource Utilization: Results from the MERGE Registry. Blood. 132(Supplement 1). 4311–4311. 5 indexed citations
10.
Salim, Ozan, Tayfur Toptaş, Burhan Ferhanoğlu, et al.. (2016). Azacitidine versus decitabine in patients with refractory anemia with excess blast—Results of multicenter study. Leukemia Research. 45. 82–89. 13 indexed citations
11.
Atagündüz, Işık, et al.. (2016). Effects of Deeper Molecular Responses on Outcomes in Chronic Myeloid Leukemia Patients in Chronic Phase Treated With Imatinib Mesylate. Clinical Lymphoma Myeloma & Leukemia. 17(2). 120–125. 2 indexed citations
12.
Uzay, Ant, et al.. (2015). Myelodysplastic syndrome with t(9;22)(p24;q11.2), a BCR-JAK2 fusion: case report and review of the literature. International Journal of Hematology. 102(3). 383–387. 9 indexed citations
13.
Atagündüz, Işık, et al.. (2014). Aplastic Anemia Associated with Oral Terbinafine: A Case Report and Review of the Literature. Turkish Journal of Hematology. 31(4). 411–416. 4 indexed citations
14.
Uzay, Ant, et al.. (2012). The Prognostic Value of CD49d Expression in Turkish Patients with Chronic Lymphocytic Leukemia. Turkish Journal of Hematology. 29(4). 354–360. 4 indexed citations
15.
Uzay, Ant, Tayfur Toptaş, Işık Kaygusuz, et al.. (2012). The prognostic value of CD49d expression in Turkish patients with chronic lymphocytic leukemia. SHILAP Revista de lepidopterología. 2 indexed citations
16.
Kaygusuz, Işık, Mehmet Koç, Hakkı Arikan, et al.. (2010). Focal Segmental Glomerulosclerosis Associated with Idiopathic Myelofibrosis. Renal Failure. 32(2). 273–276. 8 indexed citations
17.
Beksaç, Meral, Rauf Haznedar, Tülin Tuğlular, Hakan Özdoğu, & İsmet Aydoğdu. (2009). Addition of Thalidomide (T) to Oral Melphalan/Prednisone (MP) in Patients with Multiple Myeloma: Initial Results of a Randomized Trial from the Turkish Myeloma Study Group. Dspace Repository (Marmara Üniversitesi). 3 indexed citations
18.
Çeti̇ner, Mustafa, Taflan Salepçi, Mahmut Gümüş, et al.. (2006). Rituximab-CHOP Versus CHOP Alone in Patients with Diffuse Large B Cell Lymphoma.. Blood. 108(11). 4708–4708. 2 indexed citations
19.
Çeti̇ner, Mustafa, Cafer Adıgüzel, Işık Kaygusuz, et al.. (2004). Bone marrow necrosis in a patient with non-Hodgkin lymphoma.. PubMed. 21(2). 97–100. 4 indexed citations
20.
Tuğlular, Tülin, Ahmet Tezel, Erol Avşar, et al.. (1998). Thrombophilia and inflammatory bowel disease. European Journal of Gastroenterology & Hepatology. 10(10). 827–830. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alexander Coltoff Breakdown of academic impact, for papers by Mathijs Willemsen Breakdown of academic impact, for papers by Uroš Markovic Breakdown of academic impact, for papers by Hiraku Mori Breakdown of academic impact, for papers by Caroline Mayeur‐Rousse Breakdown of academic impact, for papers by Ana Kerguelen Breakdown of academic impact, for papers by Federica Portale Breakdown of academic impact, for papers by Norihiro Murakami Breakdown of academic impact, for papers by Zefarina Zulkafli Breakdown of academic impact, for papers by E. Küenzlen
Rankless by CCL
2026